Full Investigation · Competition Bureau · 2003–2026
Project False Hope: The Competition Bureau's War on Cancer Fraud, Eighteen Years On
In March 2008 Canada's Competition Bureau announced a crackdown on websites selling false cancer cures, called it one of the most despicable forms of fraud, and promised enforcement against anyone who did not comply. Nearly a hundred sites were asked to change their claims. One company was publicly named. No penalty against any of them has been found.
Before: the one cancer case the Bureau took to court
The Bureau had shown what it could do. In February 2003 it executed search warrants in Ontario and British Columbia against CSCT Inc., which sold “Cell Specific Cancer Therapy”, also called Zoetron, from offices in Kitchener, Ontario and Penticton, B.C. The company sent patients to clinics in Tijuana, the Dominican Republic, Switzerland and Spain, claimed to have treated more than 850 people, and charged US$15,000 to $20,000 a course, travel extra. The U.S. Federal Trade Commission froze its American accounts and closed its websites, and Mexican authorities closed the last clinic.
On 2 August 2005 the Bureau announced criminal charges against the two principals, Michael Reynolds of Toronto and John Armstrong of Penticton: ten counts each of knowingly or recklessly making false or misleading representations under the Competition Act, and one count each of defrauding the public of more than $5,000 under the Criminal Code. Its deputy commissioner said the false hope was a greater concern than the money. The investigation had drawn in Toronto, Ontario and York police, the RCMP, the U.S. Postal Inspection Service, Britain's Office of Fair Trading and police in three European countries.
How those charges ended has not been found. This site's Zoetron page was written from the American side of the case and says no one was criminally charged; that is wrong for Canada, and will be corrected.
The launch, March 2008
Project False Hope was announced as an education and enforcement initiative. The Bureau said it had already found dozens of Canadian-operated websites offering cancer products that raised concerns under the false and misleading provisions of the Competition Act, and that 92 per cent of them had complied with its demand to change or remove the claims. Its acting deputy commissioner, Andrea Rosen, said swindling people with cancer was one of the most despicable forms of fraud.
It launched two online tools, “Anatomy of an Online Health Scam” and a Health Fraud Awareness Quiz, and promised that it would take additional enforcement action against the remaining sites as required. Its slogan: Fraud: Recognize it. Report it. Stop it. — the same words that headed this site's cancer page for years.
A year later
When the Globe and Mail followed up, the count had grown to nearly 100 sites, and the Bureau explained its method. Rather than pursue binding enforcement, which takes a long time, it had asked companies to remove claims it considered false or misleading; in more than 90 per cent of cases they did. Companies could also submit evidence for their claims.
The one company named
The Bureau's one public example was an Edmonton centre that agreed to stop making cancer claims and posted corrective notices on its websites offering customers refunds. Its products, the Globe reported, included an infrared sauna, a “Magnapulse”, and a Papimi.
In December 2007 — three months before Project False Hope was launched — Health Canada had issued a stop-sale and recall letter to the makers of the Pap-Ion Magnetic Inductor, the PAP-IMI, and asked border officials to detain it. The unlicensed device was promoted for cancer and AIDS, Health Canada said it might be linked to injury and death in the United States, and it had been promoted at wellness clinics across the country.
What “92 per cent complied” means
- No names. Apart from Edmonton, the companies were never identified. A patient searching a product's name would find no Bureau record of it.
- No penalties. Removing a claim when asked carried no fine, no prohibition order and no admission.
- No restitution. Except where a company volunteered it, nobody who had already paid was refunded.
- No published follow-up. No later count of how many sites put their claims back, or how many new ones appeared, has been found.
- No “additional enforcement”. The action promised against the remaining eight per cent has not been located.
Voluntary compliance is not worthless; it is fast, and it removes some claims from public view. But a website edited at a regulator's request can be edited back, and the products themselves rarely went anywhere. “Vitamin B17” capsules are still sold openly in Canada. Rife-type frequency generators are still advertised. Hydrazine sulfate, which failed every trial, was still being promoted to cancer patients.
The law the Bureau has
The Competition Act is unusually well suited to cancer claims. Section 74.01(1)(b) forbids any claim about a product's performance or effectiveness that is not based on adequate and proper testing done before the claim is made. The burden is on the advertiser, not the Bureau. It covers services — a clinic's treatment program — as well as products, and it does not depend on whether Health Canada has licensed anything. Penalties on a first order run to millions of dollars for a company, with prohibition orders, corrective notices and restitution available. Section 52 makes the same conduct a criminal offence, which is what was used against CSCT.
What would answer the question
The Bureau holds the files. An access-to-information request for Project False Hope's case records — the list of sites contacted, the compliance letters, any referrals for “additional enforcement”, and the final disposition of the 2005 CSCT charges — would show what the 92 per cent actually was. Anyone who comes across a cancer-cure claim today can report it to the Bureau; this site's complaints guide lists the routes, with contact details checked in 2026.
Related on QuackeryWatch
Sources
- Competition Bureau. “Project False Hope unveiled — Competition Bureau combats cancer fraud through education and enforcement.” 12 March 2008.
- “Clampdown on cancer scammers.” Globe and Mail, c. 2009.
- Competition Bureau. “Criminal charges laid in cancer treatment scam following Competition Bureau investigation.” 2 August 2005.
- Health Canada. “Use of unlicensed Pap-Ion Magnetic Inductor may pose health risk.” 28 December 2007.
- Competition Bureau news releases on Cellotherm (2005–06), AbTronic X2 (January 2018), NuvoCare Health Sciences (2020–22), and the Health Canada–Competition Bureau memorandum of understanding (March 2024).
- Competition Act, R.S.C. 1985, c. C-34, ss. 52 and 74.01(1)(b).
The Edmonton company is named because the Bureau named it and it agreed to the terms described; this page makes no finding about it beyond that. Charges are not convictions; no outcome of the 2005 charges has been located. Corrections are welcome and are recorded on the page.